[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492855":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":34,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"National Society for Neurosonology and Cerebral Circulation","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Igor A Voznjuk, Prof","First St. Petersburg State Medical University named after I.P. Pavlov","STUDY_DIRECTOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Tatiana Kharitonova","CONTACT","+79217450431","tvh2001@mail.ru",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze","RECRUITING","Saint Petersburg","Russia",{"type":26,"coordinates":27},"Point",[28,29],30.31413,59.93863,{"lat":29,"lon":28},[32],{"name":33,"role":16,"phone":7,"phoneExt":7,"email":7},"Ekaterina Gogoleva",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100492855",false,"NCT05697575","Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","REPIN","Inclusion Criteria:\n\n* Age 18-85 ;\n* Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;\n* Thrombolytic therapy with the drug \"non-immunogenic staphylokinase\" is planned or has already been performed.\n\nExclusion Criteria:\n\n* Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;\n* The presence of a contraindication to thrombolytic therapy of ischemic stroke;\n* Pregnancy or lactation.","ALL","18 Years","85 Years",{"count":47,"type":48},336,"ESTIMATED","1 Year","OBSERVATIONAL","The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.",[53],"Acute Stroke",[55,56,57],"stroke thrombolysis","acute ischemic stroke","reperfusion","2026-04-09",{"date":60,"type":61},"2026-04-13","ACTUAL",{"date":63,"type":61},"2023-02-01",{"date":65,"type":48},"2030-05-10",{"name":5,"class":6},1]